Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5–1131T→C Gene Variation | Zendy

Montse Guardiola | Zendy; Raimón Ferré | Zendy; Juliana Salazar | Zendy; Carlos AlonsoVillaverde | Zendy; Blai Coll | Zendy; Sandra Parra | Zendy; L. Masana | Zendy; Josep Ribalta | Zendy

Open Access

Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5–1131T→C Gene Variation

Author(s) -

Montse Guardiola,

Raimón Ferré,

Juliana Salazar,

Carlos AlonsoVillaverde,

Blai Coll,

Sandra Parra,

L. Masana,

Josep Ribalta

Publication year - 2006

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2006.069583

Subject(s) - dyslipidemia , human immunodeficiency virus (hiv) , protease inhibitor (pharmacology) , protease , gene , medicine , virology , biology , genetics , viral load , antiretroviral therapy , enzyme , disease , biochemistry

Hyperlipidemia associated with the protease inhibitor (PI) component of highly active antiretrovial treatment can lead to accelerated atherosclerosis. The apolipoprotein A-V (APOA5) gene, which affects VLDL production and lipolysis, may play a role in PI-induced hyperlipidemia, particularly in individuals with the APOA5-1131T-->C genotype.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research